Continuous infusion of furosemide versus intermittent boluses in acute decompensated heart failure: Effect on thoracic fluid content

The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology
Dalia RagabMohamed Saad

Abstract

The administration of loop diuretics in the management of acute decompensated heart failure (ADHF) whether IV boluses or continuous infusion is still controversial. We intended to evaluate differences between the two administration routes on the thoracic fluid content (TFC) and the renal functions. Sixty patients with ADHF admitted to the critical care medicine department (Cairo University, Egypt) were initially enrolled in the study. Twenty patients were excluded due to EF > 40%, myocardial infarction within 30 days, and baseline serum creatinine level > 4.0 mg/dL. Furosemide (120 mg/day) was given to the remaining 40 pts who continued the study after 1:1 randomization to either continuous infusion (group-I, 20 pts) or three equal intermittent daily doses (group-II, 20 pts). Subsequent dose titration was allowed after 24 h, but not earlier, according to patient's response. No other diuretic medications were allowed. All patients were daily evaluated for NYHA class, urine output, TFC, body weight, serum K+, and renal chemistry. The median age (Q1-Q3) was 54.5 (43.8-63.8) years old with 24 (60%) males. Apart from TFC which was significantly higher in group-I, the admission demographic, clinical, laboratory and co-morbid conditio...Continue Reading

References

Jan 1, 1987·British Heart Journal·J BaylissP Poole-Wilson
Dec 1, 1983·American Journal of Surgery·J G CopelandD F Larson
Aug 1, 1996·Journal of the American College of Cardiology·T P DormansP Smits
Feb 1, 2000·The American Journal of the Medical Sciences·A Greenberg
Jan 9, 2003·JAMA : the Journal of the American Medical Association·Margaret M RedfieldRichard J Rodeheffer
Oct 18, 2003·Congestive Heart Failure·Clyde Yancy, William T Abraham
Apr 10, 2004·Congestive Heart Failure·John E Strobeck, Marc A Silver
Apr 10, 2004·Congestive Heart Failure·Charles L SpringfieldChristian Sebat
Jul 22, 2005·The Cochrane Database of Systematic Reviews·D R K SalvadorF E R Punzalan
Sep 7, 2006·The Annals of Pharmacotherapy·Brian E Gulbis, Anne P Spencer
Aug 19, 2007·Heart·Arend Mosterd, Arno W Hoes
Jun 30, 2009·European Heart Journal·Peter S PangUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators
Dec 8, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Mohammad SarrafRobert W Schrier
Feb 27, 2010·Journal of Cardiovascular Medicine·Filippo BrandimarteMihai Gheorghiade
Mar 9, 2010·Journal of Cardiac Failure·Margaret R ThomsonAdrian B Van Bakel
Mar 4, 2011·The New England Journal of Medicine·G Michael FelkerUNKNOWN NHLBI Heart Failure Clinical Research Network
May 24, 2011·Expert Opinion on Drug Metabolism & Toxicology·Nadia AspromonteClaudio Ronco
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Rajaa F FarisAndrew J S Coats
Jun 30, 2014·Critical Care : the Official Journal of the Critical Care Forum·Alberto PalazzuoliClaudio Ronco
Oct 11, 2016·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Saulius SadauskasAndrius Macas

❮ Previous
Next ❯

Software Mentioned

DOSE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.